Literature DB >> 23707642

Schizoaffective Disorder in the DSM-5.

Dolores Malaspina1, Michael J Owen, Stephan Heckers, Rajiv Tandon, Juan Bustillo, Susan Schultz, Deanna M Barch, Wolfgang Gaebel, Raquel E Gur, Ming Tsuang, Jim Van Os, William Carpenter.   

Abstract

Characterization of patients with both psychotic and mood symptoms, either concurrently or at different points during their illness, has always posed a nosological challenge and this is reflected in the poor reliability, low diagnostic stability, and questionable validity of DSM-IV Schizoaffective Disorder. The clinical reality of the frequent co-occurrence of psychosis and Mood Episodes has also resulted in over-utilization of a diagnostic category that was originally intended to only rarely be needed. In the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, an effort is made to improve reliability of this condition by providing more specific criteria and the concept of Schizoaffective Disorder shifts from an episode diagnosis in DSM-IV to a life-course of the illness in DSM-5. When psychotic symptoms occur exclusively during a Mood Episode, DSM-5 indicates that the diagnosis is the appropriate Mood Disorder with Psychotic Features, but when such a psychotic condition includes at least a two-week period of psychosis without prominent mood symptoms, the diagnosis may be either Schizoaffective Disorder or Schizophrenia. In the DSM-5, the diagnosis of Schizoaffective Disorder can be made only if full Mood Disorder episodes have been present for the majority of the total active and residual course of illness, from the onset of psychotic symptoms up until the current diagnosis. In earlier DSM versions the boundary between Schizophrenia and Schizoaffective Disorder was only qualitatively defined, leading to poor reliability. This change will provide a clearer separation between Schizophrenia with mood symptoms from Schizoaffective Disorder and will also likely reduce rates of diagnosis of Schizoaffective Disorder while increasing the stability of this diagnosis once made.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Affective disorder; DSM-5; Depression; Diagnosis; Mania; Psychosis; Schizoaffective Disorder; Schizophrenia

Mesh:

Year:  2013        PMID: 23707642     DOI: 10.1016/j.schres.2013.04.026

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  29 in total

1.  Treatment resistant somatic delusions in bipolar disorder.

Authors:  Hannah Slattery; Michael Nance
Journal:  BMJ Case Rep       Date:  2015-07-07

2.  The implications of the shared genetics of psychiatric disorders.

Authors:  Michael C O'Donovan; Michael J Owen
Journal:  Nat Med       Date:  2016-10-26       Impact factor: 53.440

3.  A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses.

Authors:  Faith M Hanlon; Ronald A Yeo; Nicholas A Shaff; Christopher J Wertz; Andrew B Dodd; Juan R Bustillo; Shannon F Stromberg; Denise S Lin; Swala Abrams; Jingyu Liu; Andrew R Mayer
Journal:  Schizophr Res       Date:  2019-01-31       Impact factor: 4.939

Review 4.  Distinguishing bipolar disorder from other psychiatric disorders in children.

Authors:  Manpreet K Singh; Terence Ketter; Kiki D Chang
Journal:  Curr Psychiatry Rep       Date:  2014-12       Impact factor: 5.285

5.  How Well Does the DSM-5 Capture Schizoaffective Disorder?

Authors:  Gordon Parker
Journal:  Can J Psychiatry       Date:  2019-06-10       Impact factor: 4.356

6.  Functional outcome and service engagement in major depressive disorder with psychotic features: comparisons with schizophrenia, schizoaffective disorder and bipolar disorder in a 6-year follow-up of the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).

Authors:  Tara Kingston; Paul J Scully; David J Browne; Patrizia A Baldwin; Anthony Kinsella; Eadbhard O'Callaghan; Vincent Russell; John L Waddington
Journal:  CNS Neurosci Ther       Date:  2018-03-25       Impact factor: 5.243

7.  A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.

Authors:  Taiwo Babatope; Jigar Chotalia; Rania Elkhatib; Satyajit Mohite; Joel Shah; Sumana Goddu; Ruchir Arvind Patel; Osarhiemen Ruth Aimienwanu; Devanshu Patel; Titilayo Makanjuola; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2016-12

8.  Subclinical psychosis syndromes in the general population: results from a large-scale epidemiological survey among residents of the canton of Zurich, Switzerland.

Authors:  W Rössler; V Ajdacic-Gross; H Haker; S Rodgers; M Müller; M P Hengartner
Journal:  Epidemiol Psychiatr Sci       Date:  2013-11-26       Impact factor: 6.892

9.  The Direct and Indirect Effects of Paliperidone Extended-release on Depressive Symptoms in Schizoaffective Disorder: A Path Analysis.

Authors:  Ibrahim Turkoz; Dong-Jing Fu; Cynthia A Bossie; Larry Alphs
Journal:  Innov Clin Neurosci       Date:  2015 Nov-Dec

10.  Treatment Capacity and Clinical Outcomes for Patients With Schizophrenia Who Were Treated With Electroconvulsive Therapy: A Retrospective Cohort Study.

Authors:  Joanne E Plahouras; Gerasimos Konstantinou; Tyler S Kaster; Daniel Z Buchman; George Foussias; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.